Latest Content

Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.

Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.

A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.

September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.

Dr. Nitin Ohri explains how radiation treats cancer, how often treatment is needed, common side effects and how to tell if radiation is working.

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

Breast cancer treatment has changed dramatically since 2021. Here are the key FDA approvals, year by year, and what they mean for patients.

Choosing hospice care brought comfort, support and precious time for one family as they navigated cancer, caregiving and bringing a loved one home.

Learn how to cope with life after cancer treatment with Dr. Eric Bengtsen, a psycho-oncology psychiatrist at Memorial Sloan Kettering Cancer Center.

On National Previvor Day, learn what it means to carry an inherited gene change like BRCA1 or BRCA2, and the screening and surgery options that lower risk.

Patients with HPV-associated oropharyngeal cancer who received 23% less radiation reported fewer swallowing, voice and dry mouth problems six months after treatment.

Heather Curley discusses her leptomeningeal disease diagnosis, joining an experimental vaccine trial and the milestones she has been able to share with her daughter.

A phase 3 trial presented at ASTRO 2026 found that giving focused radiation in three to five sessions, instead of one, lowered the chance of cancer returning at the surgery site, and patients lived longer.